Inhibrx reports FY2024 net income of $1.7B driven by spin-off gain; secures $100M loan

Inhibrx Biosciences, Inc.

Net income of $1.7B (EPS $114.01 basic) vs net loss of $241.4M in FY2023; gain from Sanofi INBRX-101 sale.
Cash of $152.6M at Dec 31, 2024; after $100M Oxford loan in Jan 2025, $230.5M as of Feb 28, 2025.
R&D expense $203.7M (FY2024) vs $191.6M; includes $25.9M stock option acceleration from spin-off.
G&A expense $127.9M (FY2024) vs $29.4M; includes $68.1M spin-off costs and $15.2M option acceleration.
Ozekibart Phase 1 CRC data: 1 CR, 3 PRs, median PFS 7.85 mo; expansion cohort enrolling up to 50 patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.